InxMed is a clinical-stage biotech company dedicated to developing innovative, individualized medicines with international impact.
InxMed is a clinical-stage biotech company focusing on developing "Best-in-Disease Combination" medicines to bring novel treatment options for patients. Our innovations are inspired by patients and driven by an in-depth understanding of disease biology and pharmacology. InxMed is committed to building a translational platform equipped with global-level top-notch know-how and efficient execution capabilities.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 21, 2022 | Debt Financing | $10M | 1 | SPD Silicon Valley Bank (SSVB) | — | Detail |
May 8, 2022 | Series B | $15M | 1 | Hyfinity Investments | — | Detail |
Mar 3, 2022 | Series B | $50M | 4 | CS Capital | — | Detail |
Sep 4, 2020 | Series A | ¥130M | 4 | Ennovation Ventures China Growth Capital | CGC | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
SPD Silicon Valley Bank (SSVB) | Yes | Debt Financing |
Hyfinity Investments | Yes | Series B |
CS Capital | Yes | Series B |
China Growth Capital | CGC | Yes | Series A |
Ennovation Ventures | — | Series B |
AIHC Capital | — | Series B |
HosenCare Brothers | — | Series B |
Grand Yangtze Capital | — | Series A |
InnoMed Capital | — | Series A |